Statement on motion sickness.
D000284:Administration, Oral; D002170:Canada / Q000453:epidemiology; D000075202:Contraindications; D003937:Diagnosis, Differential; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D009041:Motion Sickness / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D014195:Travel
D006634:Histamine H1 Antagonists; D018727:Muscarinic Antagonists; D012702:Serotonin Antagonists